FACTBOX-Timeline and facts about obesity drugs

WASHINGTON, Sept 15 (Reuters) - An advisory panel that met Wednesday was evenly divided on whether a weight-loss drug from Abbott Laboratories was too dangerous to stay on the market. [ID:nN15144589]